Genta drug's efficacy questioned by FDA

The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.

Related Videos
Related Content

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

FDA Approves Retifanlimab-Dlwr for the Treatment of Metastatic or Recurrent Locally Advanced MCC

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

AAD 2023 Pearls from Zoe Diana Draelos, MD

March 22nd 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.